Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). It focuses on products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions.
Contact
Basilea Pharmaceutica Ltd.
Grenzacherstrasse 487
PO Box
4005 Basel
Switzerland
One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold…
The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change…
Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF…
David Veitch, the CEO of Basilea Pharmaceutica, shares his insights into the company’s strategic vision to become a global leader in the antifungal and antibacterial space. Veitch discusses the unique…
Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
See our Cookie Privacy Policy Here
